Kalaris Therapeutics, Inc. (Nasdaq: KLRS) announced it will present Phase 1a clinical data for its investigational drug TH103 at the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE